Welcome to our dedicated page for Alpine Immune Sciences news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences stock.
Founded in 2015, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a leading clinical-stage biotechnology company dedicated to developing innovative protein-based immunotherapies to treat autoimmune and inflammatory diseases. Alpine leverages its unique understanding of immunology, particularly recombinant protein-based immunotherapies, to modify the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Alpine's standout product, povetacicept (ALPN-303), is a dual antagonist of the BAFF and APRIL cytokines. This product is currently in phase 2 development and has demonstrated potential best-in-class efficacy for treating IgA nephropathy (IgAN). IgAN is a serious, progressive kidney disease with no approved therapies that target its underlying cause. Povetacicept has exhibited promising results in reducing proteinuria, stabilizing renal function, and reducing key disease-related biomarkers.
Additionally, Alpine has a robust pipeline, including acazicolcept (ALPN-101), a first-in-class dual inhibitor targeting the CD28 and ICOS T-cell costimulatory pathways. This drug is being investigated for treating systemic lupus erythematosus (SLE) and other autoimmune diseases. Alpine's research and development capabilities are enhanced by strategic collaborations with leading global biopharmaceutical companies, propelling its efforts to create multifunctional immunotherapies that improve patients' lives.
The company has been highly productive in the past year, achieving significant milestones, such as the phase 2 study of acazicolcept in SLE, a pivotal phase 3 trial of povetacicept in IgAN planned for the second half of 2024, and successful financial activities supporting ongoing and future development projects.
Alpine Immune Sciences remains committed to innovation, with ongoing studies in various autoimmune diseases and strategic goals aligning with its mission to lead a new wave of immune therapeutics.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced its participation in two major investor conferences in
Horizon Therapeutics and Alpine Immune Sciences have announced an exclusive licensing agreement for the development of up to four preclinical candidates. Horizon will pay
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The event will be accessible via a live webcast on the company's investor relations page, with a replay available for 90 days post-event. Alpine focuses on developing innovative immunotherapies for cancer and autoimmune diseases, leveraging advanced protein engineering technologies. Collaborations with global biopharmaceutical companies enhance their diverse pipeline of clinical and preclinical candidates.
Alpine Immune Sciences (NASDAQ: ALPN) reported significant progress in Q3 2021, including a $91M securities offering to enhance developmental efforts. The company aims to accelerate the clinical evaluation of ALPN-303 and ALPN-202, with the former's phase 1 study set to begin by year-end 2021. ALPN-303 data showcased its potential during the ACR Convergence 2021 Annual Meeting. Financially, ALPN reported net losses of $13.5M with collaboration revenue rising to $8.5M, largely due to the AbbVie Agreement. Cash reserves are projected to sustain operations through 2023.
Alpine Immune Sciences (NASDAQ: ALPN) presented promising data on ALPN-303, an engineered dual BAFF/APRIL inhibitor, at the ACR Convergence 2021 meeting. The preclinical study shows that ALPN-303 exhibits over 5-fold greater potency than wild-type TACI-Fc in inhibiting B cell cytokines. Results from animal models indicate that it effectively reduces harmful B cell populations while improving renal function in lupus models. A Phase 1 clinical trial for healthy adults is set to begin in Q4 2021, aiming to evaluate the safety and efficacy of ALPN-303.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has announced a definitive securities purchase agreement, raising approximately
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will present at several investor conferences in September 2021. Key events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Oppenheimer Fall Healthcare Summit on September 20, and Cantor Global Healthcare Conference on September 29. Each presentation will be available via webcast on the company's investor relations website. Alpine is focused on innovative immunotherapy treatments for cancer and autoimmune diseases, emphasizing collaborations and a diverse pipeline.
Alpine Immune Sciences, a clinical-stage immunotherapy firm, reported a productive second quarter with significant milestones. Key highlights include the initiation of the Synergy Phase 2 trial of acazicolcept in lupus patients, achieving $45 million in development milestones with AbbVie, and presenting promising data on ALPN-202 at ASCO 2021. The firm had cash resources of $100.4 million as of June 30, 2021, and expects to fund operations through 2023. The company remains on track to initiate Phase 1 for ALPN-303 in Q4 2021, reinforcing its strong pipeline in immunology and oncology.
Alpine Immune Sciences (NASDAQ:ALPN) will release its second quarter 2021 financial results on August 10, 2021, after market close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. Additionally, the company will participate in the Bernstein CD28 Day on August 9 and the Wedbush PacGrow Healthcare Virtual Conference on August 11. The company focuses on developing innovative immunotherapies for cancer and autoimmune diseases, supported by strategic collaborations and a diverse pipeline.
Alpine Immune Sciences (NASDAQ: ALPN) has announced a collaboration with Merck to evaluate the combination of its ALPN-202 with Merck’s KEYTRUDA in a clinical trial named NEON-2. Initiated in June 2021, this trial aims to assess the safety and efficacy of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor that has shown superior efficacy in preclinical studies. The collaboration is expected to enhance clinical insights for ALPN-202, which is also being evaluated in the ongoing NEON-1 monotherapy trial for advanced malignancies.
FAQ
What is the current stock price of Alpine Immune Sciences (ALPN)?
What is the market cap of Alpine Immune Sciences (ALPN)?
What does Alpine Immune Sciences, Inc. specialize in?
What is povetacicept (ALPN-303)?
What are the core focus areas of Alpine Immune Sciences?
What recent achievement has Alpine Immune Sciences accomplished?
What is acazicolcept (ALPN-101)?
What collaborations has Alpine Immune Sciences engaged in?
What is the ticker symbol for Alpine Immune Sciences?
When was Alpine Immune Sciences founded?
What is the mission of Alpine Immune Sciences?
Where can more information about Alpine Immune Sciences be found?
